Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: Ibogaine derivatives - MindMed/Nextage Therapeutics

Next Previous
Drug Profile

Research programme: Ibogaine derivatives - MindMed/Nextage Therapeutics

Latest Information Update: 28 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mindmed; Nextage Therapeutics
  • Class Drug withdrawal therapies; Indoles; Rauwolfia alkaloids; Small molecules
  • Mechanism of Action Excitatory amino acid antagonists; Nicotinic receptor antagonists; NMDA receptor agonists; Opioid receptor antagonists; Serotonin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Opioid-related disorders

Most Recent Events

  • 28 Jun 2025 No recent reports of development identified for research development in Opioid-related-disorders in Israel
  • 28 Jun 2025 No recent reports of development identified for research development in Opioid-related-disorders in USA
  • 24 May 2021 MindMed and Nextage Therapeutics executes Memorandum of Understanding (MOU) to launch of an exclusive collaborative development program to optimize the delivery of certain psychedelic drug candidates

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top